Abstract
OPLS discriminant analysis (OPLS-DA) was successfully applied for the selection of a limited number of gene transcripts necessary to discriminate PTPN11 and RAS mutated cells in acute lymphoblastic leukaemia (ALL) patients. The original set of 273 variables with VIP (1) values higher than 2.0 in the OPLS-DA model could be further reduced to 200 by elimination of less informative variables in the PCA class models adopted for SIMCA classification. The above 200 transcripts not only achieve a satisfactory discrimination accuracy between PTPN11 and RAS mutated cells but also indicate clearly that wild type samples belong to none of the mutated class models. In this list it was possible to identify candidate genes that could be involved in the molecular mechanisms discriminating PTPN11 and RAS mutations in ALL. Among them CBFA2T2, a member of the “ETO” family, is known because of its homology and association with the product of RUNX1-CBFA2T1 gene fusion generated by t(8;21) translocation, one frequent cause of acute myeloid leukemia.
Keywords: ALL, OPLS, leukaemia, gene transcripts, mutations, SIMCA classification, Partial Least Squares, PLS, PLS-DA, SIMCA, PDQuest, OPLS-DA, acute lymphoblastic leukaemia, PTPN11, RAS, PCA, DModX, DCrit, 17AAG, EPH136, CBFA2T2, MTGR1, CBFA2T1, MTG8, ETO, N-CoR, SMRT, mSin3A, a, HDAC, RUNX1-CBFA2T1
Combinatorial Chemistry & High Throughput Screening
Title: OPLS-DA as a Suitable Method for Selecting a Set of Gene Transcripts Discriminating RAS- and PTPN11-Mutated Cells in Acute Lymphoblastic Leukaemia
Volume: 14 Issue: 1
Author(s): Giuseppe Musumarra, Daniele F. Condorelli and Cosimo G. Fortuna
Affiliation:
Keywords: ALL, OPLS, leukaemia, gene transcripts, mutations, SIMCA classification, Partial Least Squares, PLS, PLS-DA, SIMCA, PDQuest, OPLS-DA, acute lymphoblastic leukaemia, PTPN11, RAS, PCA, DModX, DCrit, 17AAG, EPH136, CBFA2T2, MTGR1, CBFA2T1, MTG8, ETO, N-CoR, SMRT, mSin3A, a, HDAC, RUNX1-CBFA2T1
Abstract: OPLS discriminant analysis (OPLS-DA) was successfully applied for the selection of a limited number of gene transcripts necessary to discriminate PTPN11 and RAS mutated cells in acute lymphoblastic leukaemia (ALL) patients. The original set of 273 variables with VIP (1) values higher than 2.0 in the OPLS-DA model could be further reduced to 200 by elimination of less informative variables in the PCA class models adopted for SIMCA classification. The above 200 transcripts not only achieve a satisfactory discrimination accuracy between PTPN11 and RAS mutated cells but also indicate clearly that wild type samples belong to none of the mutated class models. In this list it was possible to identify candidate genes that could be involved in the molecular mechanisms discriminating PTPN11 and RAS mutations in ALL. Among them CBFA2T2, a member of the “ETO” family, is known because of its homology and association with the product of RUNX1-CBFA2T1 gene fusion generated by t(8;21) translocation, one frequent cause of acute myeloid leukemia.
Export Options
About this article
Cite this article as:
Musumarra Giuseppe, F. Condorelli Daniele and G. Fortuna Cosimo, OPLS-DA as a Suitable Method for Selecting a Set of Gene Transcripts Discriminating RAS- and PTPN11-Mutated Cells in Acute Lymphoblastic Leukaemia, Combinatorial Chemistry & High Throughput Screening 2011; 14 (1) . https://dx.doi.org/10.2174/1386207311107010036
DOI https://dx.doi.org/10.2174/1386207311107010036 |
Print ISSN 1386-2073 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5402 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Monoclonal Antobodies: Application in Radiopharmacy
Current Radiopharmaceuticals The Role of Foxp3 in Regulatory T Cell Differentiation and Function
Current Immunology Reviews (Discontinued) Targeting mTOR Pathways in Human Malignancies
Current Pharmaceutical Design Ovarian Toxicity: From Environmental Exposure to Chemotherapy
Current Pharmaceutical Design The Significance of Ubiquitin Proteasome Pathway in Cancer Development
Recent Patents on Anti-Cancer Drug Discovery Role of the Hypoxic Microenvironment in the Antitumor Activity of Tyrosine Kinase Inhibitors
Current Medicinal Chemistry Plants vs. Cancer: A Review on Natural Phytochemicals in Preventing and Treating Cancers and Their Druggability
Anti-Cancer Agents in Medicinal Chemistry Towards Liver-Directed Gene Therapy for Crigler-Najjar Syndrome
Current Gene Therapy Development of Doxorubicin Quantification by Reductive Amination
Current Analytical Chemistry Anti-Angiogenic and Anti-Inflammatory Effects of Statins: Relevance to Anti-Cancer Therapy
Current Cancer Drug Targets An Overview of Naturally Occurring Histone Deacetylase Inhibitors
Current Topics in Medicinal Chemistry Natural Endoperoxides as Drug Lead Compounds
Current Medicinal Chemistry Drug-Related Cardiotoxicity for the Treatment of Haematological Malignancies in Elderly
Current Pharmaceutical Design Microtubule Targeting Agents: A Benchmark in Cancer Therapy
Current Drug Therapy Stereoselective Metabolic and Pharmacokinetic Analysis of the Chiral Active Components from Herbal Medicines
Current Pharmaceutical Analysis A Targeted Therapy for Protein and Lipid Kinases in Chronic Lymphocytic Leukemia
Current Medicinal Chemistry Leptin, Ciliary Neurotrophic Factor, Leukemia Inhibitory Factor and Interleukin- 6: Class-I Cytokines Involved in the Neuroendocrine Regulation of the Reproductive Function
Current Protein & Peptide Science Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) Inhibitors
Current Medicinal Chemistry Ocular Toxicities in Cancer Therapy: Still Overlooked
Current Cancer Therapy Reviews The mTOR/4E-BP1/eIF4E Signalling Pathway as a Source of Cancer Drug Targets
Current Medicinal Chemistry